Logo image of CANG

CANGO INC/KY - ADR (CANG) Stock Fundamental Analysis

NYSE:CANG - New York Stock Exchange, Inc. - US1375861036 - ADR - Currency: USD

4.55  -0.07 (-1.52%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CANG. CANG was compared to 120 industry peers in the Specialty Retail industry. Both the profitability and financial health of CANG have multiple concerns. CANG is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

CANG had negative earnings in the past year.
The reported net income has been mixed in the past 5 years: CANG reported negative net income in multiple years.
In the past 5 years CANG reported 4 times negative operating cash flow.
CANG Yearly Net Income VS EBIT VS OCF VS FCFCANG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B 3B

1.2 Ratios

CANG has a Return On Assets of 0.04%. This is comparable to the rest of the industry: CANG outperforms 45.83% of its industry peers.
CANG has a Return On Equity (0.08%) which is in line with its industry peers.
Industry RankSector Rank
ROA 0.04%
ROE 0.08%
ROIC N/A
ROA(3y)-3.88%
ROA(5y)3.21%
ROE(3y)-6.46%
ROE(5y)4.15%
ROIC(3y)N/A
ROIC(5y)N/A
CANG Yearly ROA, ROE, ROICCANG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

Looking at the Profit Margin, with a value of 0.17%, CANG is in line with its industry, outperforming 49.17% of the companies in the same industry.
In the last couple of years the Profit Margin of CANG has grown nicely.
In the last couple of years the Operating Margin of CANG has declined.
CANG has a Gross Margin of 13.27%. This is amonst the worse of the industry: CANG underperforms 90.00% of its industry peers.
CANG's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 0.17%
GM 13.27%
OM growth 3Y61.58%
OM growth 5Y-5.43%
PM growth 3YN/A
PM growth 5Y6.57%
GM growth 3Y-7.64%
GM growth 5Y-20.99%
CANG Yearly Profit, Operating, Gross MarginsCANG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

3

2. Health

2.1 Basic Checks

CANG does not have a ROIC to compare to the WACC, probably because it is not profitable.
CANG has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for CANG has been reduced compared to 5 years ago.
Compared to 1 year ago, CANG has a worse debt to assets ratio.
CANG Yearly Shares OutstandingCANG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CANG Yearly Total Debt VS Total AssetsCANG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

CANG has an Altman-Z score of 1.04. This is a bad value and indicates that CANG is not financially healthy and even has some risk of bankruptcy.
CANG has a worse Altman-Z score (1.04) than 73.33% of its industry peers.
A Debt/Equity ratio of 0.20 indicates that CANG is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.20, CANG is in line with its industry, outperforming 60.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 1.04
ROIC/WACCN/A
WACC8.24%
CANG Yearly LT Debt VS Equity VS FCFCANG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

CANG has a Current Ratio of 1.41. This is a normal value and indicates that CANG is financially healthy and should not expect problems in meeting its short term obligations.
CANG's Current ratio of 1.41 is in line compared to the rest of the industry. CANG outperforms 50.00% of its industry peers.
CANG has a Quick Ratio of 1.41. This is a normal value and indicates that CANG is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.41, CANG belongs to the top of the industry, outperforming 82.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.41
CANG Yearly Current Assets VS Current LiabilitesCANG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.42% over the past year.
The Revenue has grown by 46.68% in the past year. This is a very strong growth!
Measured over the past years, CANG shows a very negative growth in Revenue. The Revenue has been decreasing by -11.00% on average per year.
EPS 1Y (TTM)62.42%
EPS 3YN/A
EPS 5Y0%
EPS Q2Q%-330.19%
Revenue 1Y (TTM)46.68%
Revenue growth 3Y-41.04%
Revenue growth 5Y-11%
Sales Q2Q%1531.77%

3.2 Future

Based on estimates for the next years, CANG will show a very strong growth in Earnings Per Share. The EPS will grow by 153.90% on average per year.
The Revenue is expected to decrease by -11.26% on average over the next years. This is quite bad
EPS Next Y224.75%
EPS Next 2Y153.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-33.66%
Revenue Next 2Y-11.26%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CANG Yearly Revenue VS EstimatesCANG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
CANG Yearly EPS VS EstimatesCANG Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 5 -5 10 15

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CANG. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 1.66, which indicates a rather cheap valuation of CANG.
Based on the Price/Forward Earnings ratio, CANG is valued cheaply inside the industry as 99.17% of the companies are valued more expensively.
CANG is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.13, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 1.66
CANG Price Earnings VS Forward Price EarningsCANG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

CANG's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. CANG is more expensive than 71.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 122.23
CANG Per share dataCANG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CANG's earnings are expected to grow with 153.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y153.9%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for CANG!.
Industry RankSector Rank
Dividend Yield N/A

CANGO INC/KY - ADR

NYSE:CANG (5/30/2025, 1:54:44 PM)

4.55

-0.07 (-1.52%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-27 2025-08-27
Inst Owners18.71%
Inst Owner Change-10.48%
Ins Owners1.88%
Ins Owner ChangeN/A
Market Cap472.24M
Analysts43.33
Price TargetN/A
Short Float %6.69%
Short Ratio4.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.66
P/S 1.89
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.89
EV/EBITDA 122.23
EPS(TTM)-0.03
EYN/A
EPS(NY)2.74
Fwd EY60.31%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.4
BVpS5.18
TBVpS5.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.04%
ROE 0.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 0.17%
GM 13.27%
FCFM N/A
ROA(3y)-3.88%
ROA(5y)3.21%
ROE(3y)-6.46%
ROE(5y)4.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y61.58%
OM growth 5Y-5.43%
PM growth 3YN/A
PM growth 5Y6.57%
GM growth 3Y-7.64%
GM growth 5Y-20.99%
F-ScoreN/A
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA 28.01
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.41
Quick Ratio 1.41
Altman-Z 1.04
F-ScoreN/A
WACC8.24%
ROIC/WACCN/A
Cap/Depr(3y)348.58%
Cap/Depr(5y)264.99%
Cap/Sales(3y)38.63%
Cap/Sales(5y)23.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.42%
EPS 3YN/A
EPS 5Y0%
EPS Q2Q%-330.19%
EPS Next Y224.75%
EPS Next 2Y153.9%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)46.68%
Revenue growth 3Y-41.04%
Revenue growth 5Y-11%
Sales Q2Q%1531.77%
Revenue Next Year-33.66%
Revenue Next 2Y-11.26%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-162.18%
EBIT growth 3Y-4.73%
EBIT growth 5Y-15.84%
EBIT Next Year29.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-220.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-130.21%
OCF growth 3YN/A
OCF growth 5YN/A